Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

Ads

You May Also Like

Galena Biopharma Announces Pricing of Registered Direct Offering

SAN RAMON, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a ...

Mateon Announces Issuance of US Patent for Cathepsin Inhibition

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), ...

HealthiNation and eVideon Announce New Content Distribution Partnership

HealthiNation Health Video Content Now Available on eVideon’s Hospital SystemsNEW YORK, May 16, 2018 ...